These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 34134024)

  • 1. A randomized, multicenter, crossover psychometric evaluation study of an iPad-administered cognitive test battery in participants with major depressive disorder who responded to treatment with oral antidepressants.
    Bogert J; Rofael H; Mosca K; Ross RO; Callaerts G; Wang D; Jaeger J; Narayan VA; Drevets WC; Morrison RL
    J Affect Disord; 2021 Sep; 292():261-269. PubMed ID: 34134024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].
    Robert PH; Schuck S; Dubois B; Lépine JP; Gallarda T; Olié JP; Goni S; Troy S
    Encephale; 2003; 29(3 Pt 1):266-72. PubMed ID: 12876552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual cognitive and psychosocial functional impairment in outpatients in Greece who responded to conventional antidepressant monotherapy treatments for major depressive disorder (MDD).
    Papalexi E; Galanopoulos A; Roukas D; Argyropoulos I; Michopoulos I; Douzenis A; Gkolia I; Fotiadis P; Kontis D; Zervas IM
    J Affect Disord; 2022 Oct; 314():185-192. PubMed ID: 35817305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychometric properties of the MATRICS Consensus Cognitive Battery (MCCB) in Chinese patients with major depressive disorder.
    Liang S; Yu W; Ma X; Luo S; Zhang J; Sun X; Luo X; Zhang Y
    J Affect Disord; 2020 Mar; 265():132-138. PubMed ID: 32090734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A computerized, self-administered test of verbal episodic memory in elderly patients with mild cognitive impairment and healthy participants: A randomized, crossover, validation study.
    Morrison RL; Pei H; Novak G; Kaufer DI; Welsh-Bohmer KA; Ruhmel S; Narayan VA
    Alzheimers Dement (Amst); 2018; 10():647-656. PubMed ID: 30456291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women.
    Pae CU; Mandelli L; Han C; Ham BJ; Masand PS; Patkar AA; Steffens DC; De Ronchi D; Serretti A
    Neuro Endocrinol Lett; 2008 Aug; 29(4):500-6. PubMed ID: 18766158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder.
    Lam RW; Iverson GL; Evans VC; Yatham LN; Stewart K; Tam EM; Axler A; Woo C
    J Affect Disord; 2016 Oct; 203():55-61. PubMed ID: 27280963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine.
    Subramaniapillai M; Mansur RB; Zuckerman H; Park C; Lee Y; Iacobucci M; Cao B; Ho R; Lin K; Phan L; McIntyre RS
    Compr Psychiatry; 2019 Oct; 94():152113. PubMed ID: 31404802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The THINC-Integrated Tool (THINC-it) Screening Assessment for Cognitive Dysfunction: Validation in Patients With Major Depressive Disorder.
    McIntyre RS; Best MW; Bowie CR; Carmona NE; Cha DS; Lee Y; Subramaniapillai M; Mansur RB; Barry H; Baune BT; Culpepper L; Fossati P; Greer TL; Harmer C; Klag E; Lam RW; Wittchen HU; Harrison J
    J Clin Psychiatry; 2017 Jul; 78(7):873-881. PubMed ID: 28858441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Web-based tools can be used reliably to detect patients with major depressive disorder and subsyndromal depressive symptoms.
    Lin CC; Bai YM; Liu CY; Hsiao MC; Chen JY; Tsai SJ; Ouyang WC; Wu CH; Li YC
    BMC Psychiatry; 2007 Apr; 7():12. PubMed ID: 17425774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of residual cognitive disturbances by early response of depressive symptoms to antidepressant treatments in patients with major depressive disorder.
    Sumiyoshi T; Hoshino T; Mishiro I; Hammer-Helmich L; Ge H; Moriguchi Y; Fujikawa K; Fernandez JL
    J Affect Disord; 2022 Jan; 296():95-102. PubMed ID: 34597893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
    J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The reliability and validity of PHQ-9 in patients with major depressive disorder in psychiatric hospital.
    Sun Y; Fu Z; Bo Q; Mao Z; Ma X; Wang C
    BMC Psychiatry; 2020 Sep; 20(1):474. PubMed ID: 32993604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Cognitive Function and Health Care Costs 3 Months and 6 Months After Initiating Antidepressant Medication for Depressive Disorders.
    Walker V; Patel H; Kurlander JL; Essoi B; Yang J; Mahableshwarkar AR; Samp JC; Akhras KS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):742-52, 752a-752e. PubMed ID: 26308222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSYCHOMETRIC properties of the Chinese version of the THINC-it tool for cognitive symptoms in patients with major depressive disorder.
    Hou Y; Yao S; Hu S; Zhou Q; Han H; Yu X; McIntyre RS; Shi C
    J Affect Disord; 2020 Aug; 273():586-591. PubMed ID: 32560957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence to Support Montgomery-Asberg Depression Rating Scale Administration Every 24 Hours to Assess Rapid Onset of Treatment Response.
    Johnson KM; Devine JM; Ho KF; Howard KA; Saretsky TL; Jamieson CA
    J Clin Psychiatry; 2016 Dec; 77(12):1681-1686. PubMed ID: 28086004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attention and executive functions in remitted major depression patients.
    Paelecke-Habermann Y; Pohl J; Leplow B
    J Affect Disord; 2005 Dec; 89(1-3):125-35. PubMed ID: 16324752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.
    Liebowitz MR; Yeung PP; Entsuah R
    J Clin Psychiatry; 2007 Nov; 68(11):1663-72. PubMed ID: 18052559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.